Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
testosterone 0.03% ophthalmic solution
- Development stage
- Phase 2
- Lead developer
- ORA
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Testosterone 0.03% ophthalmic solution is a topical androgen therapy developed by ORA for the treatment of meibomian gland dysfunction (MGD). Meibomian glands are specialized sebaceous glands in the eyelids that secrete meibum, a lipid-rich substance essential for stabilizing the tear film and preventing evaporation. Androgen receptors are expressed in the meibomian gland epithelial cells, and androgen signaling is a key regulator of gland function and lipid synthesis. Deficiency in local androgen levels is associated with MGD and subsequent evaporative dry eye disease. By delivering testosterone directly to the ocular surface, this formulation acts as an androgen receptor agonist to stimulate meibomian gland activity, improve the quality and quantity of meibum, and restore tear film stability.
- Other names
- testosterone ophthalmic solutiontestosterone eye drops
02
Targets
AR (Adrenergic receptors)
Beyond the preview
Go deeper on testosterone 0.03% ophthalmic solution.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on testosterone 0.03% ophthalmic solution.